10x Genomics, Inc. (NasdaqGS:TXG) will look for acquisitions. Saxonov, Serge Co-Founder, Chief Executive Officer & Director said "the way we think about acquisitions is that they're driven really by like overall product development, the product road map priorities. We think about, again, kind of what our customers need and work backwards to invest in platforms and technologies internally and also realize that we don't have monopoly in innovation. There's lots of smart people out there. And so we actually -- we're always on a lookout to see what like -- what innovations have been happening outside of our walls. And if something is out there that makes sense in the context of our long-term imperatives, we acquire those companies and those assets. And that's the philosophy that kind of led us to ReadCoor to CartaNA last year and our previous acquisitions as well. So we're always on the lookout. But that's -- it's really premised on that, our long-term strategy rather than buying things for the sake of buying them".
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.